Skip to main content

Recent News

Fighting Hydroxychloroquine Misinformation

Aug 03, 2020

JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it.”.

Read Article
Retrospective study of 20 RA pts w/ resolved hepatitis B (HBcAb+; HBsAg neg). 16/20 were Rx w/ tocilizumab & 8/20 w/ tofacitinib (nearly all HBsAb+).

Dr. John Cush @RheumNow (  View Tweet)

Aug 03, 2020
A large Latin American SLE cohort was studied; 66 (5.6%) had familial SLE & 1110 (94.4%) sporadic SLE: Familial SLE was more often associated with discoid LE (OR 1.97) & CNS dz (OR 1.65), more MSK Dz.

Dr. John Cush @RheumNow (  View Tweet)

Aug 03, 2020
Systematic literature finds a connection between ankylosing spondylitis (AS) and dementia (RR 1.19 [95% CI 1.01‐1.41]). From a total of 6562 articles reviewed, only 4 met criteria - analysis included 156418 pts. Cause? inflammation, inactivity?

Dr. John Cush @RheumNow (  View Tweet)

Aug 03, 2020
The RheumNow Podcast is up - Top 13 Rheumatology Centers in the US; anakinra & colchicine in COVID, unload the loading dose, CB2 in Scleroderma.

Dr. John Cush @RheumNow (  View Tweet)

Aug 02, 2020

Uric Acid Targeting in Gout Management

Jul 31, 2020

A study from 2 gout clinics implementing different treatment strategies has shown that a treatment strategy that aims to strictly achieve low uric acid (UA) results in a higher a rate of targetd serum UA lowering and less gout flares.

Read Article

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article
Spanish registry of 3679 SLE pts finds 13.6% had polyautoimmunity (SLE plus another autoimmune Dz), Dx as thyroiditis (8%), Sjogrens (14%) secondary APS (14%).

Dr. John Cush @RheumNow (  View Tweet)

Jul 31, 2020
Based on a small number of studies (n = 5), there is little evidence to support the superiority (efficacy & safety) of Loading dose regimens when starting biologic (abatacept, certolizumab and secukinumab) therapy. https://t.co/0lNUzTFIOK

Dr. John Cush @RheumNow (  View Tweet)

Jul 31, 2020
Sandoz rituximab biosimilar(SDZ-RTX; Rixathon) compared with reference rituximab (Ref-RTX) and shown to have same efficacy outcomes (DAS28 Remission, ACR20/50/70, CDAi/SDAI, HAQ), B cell depletion levels, adverse events & low level antidrug Abs https://t.co/0XWQ

Dr. John Cush @RheumNow (  View Tweet)

Jul 31, 2020
Fracture risk & prevalence of osteoporosis is elevated in patients with idiopathic inflammatory myopathies: cross-sectional comparison of 52 myositis and 43 RA pts.

Dr. John Cush @RheumNow (  View Tweet)

Jul 31, 2020

Colchicine Benefits COVID-19 Patients

Jul 30, 2020

A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes. Efficacy and safety must be determined in controlled clinical trials.he outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties.

Read Article
Safety & efficacy of rituximab in Older RA (>65; n=97) vs younger (<65yrs; n=276) showed no difference in drug survival over 2 yrs (72% vs 74%)or SDAI activity. BUT..

Dr. John Cush @RheumNow (  View Tweet)

Jul 30, 2020
FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder.

Dr. John Cush @RheumNow (  View Tweet)

Jul 30, 2020
Metanalysis of 10 studies ( p534 patients) shows that exercise in ankylosing spondylitis improves pain, function and disease activity. Statistically signif improvement in pain (P<0.0001), BASDAI (P <0.00001), and BASFI (P<0.00001), but not CRP and ESR.

Dr. John Cush @RheumNow (  View Tweet)

Jul 30, 2020
Lenabasum (cannabinoid rcptr agonist) studied in Systemic Sclerosis - LEN (n=27) vs PBO (n=15).
Dr. John Cush @RheumNow (  View Tweet)
Jul 29, 2020
The only thing worse than bad covid research is a meta-analysis of bad covid research

Vinay Prasad @VPrasadMDMPH (  View Tweet)

Jul 29, 2020
Important finding of marked lung fibrosis (scarring) after severe #COVID19 in 8 patients https://t.co/Akp6jVXmB9 @TheLancetInfDis (first complete pathologic description of this finding) https://t.co/QCuri3olgs
Eric Topol @EricTopol (  View Tweet)
Jul 29, 2020
I have a rheumatology joke but it’s painful https://t.co/TUj1nY4JD4

Elizabeth Graef @SituationRheum (  View Tweet)

Jul 29, 2020
Platelet Rich Plasma Versus Hyaluronic Acid in the Treatment of Knee Osteoarthritis: a Meta-Analysis of 26 randomized controlled trials #osteoarthritis #knee #PRP #HA metanalysis favours PRP! https://t.co/Z5Olucs3ku

Peter Nash @drpnash (  View Tweet)

Jul 29, 2020
×